Ashley Gallagher, Associate Editor

Results also show that no association with an increased frequency of myocarditis, venous thromboembolism, or worsening HF in these individuals.

Danish analysis looks at the relationship between the therapy and cardiovascular adverse effects, particularly arrhythmias.

Executives from CVS Health said they have multiple pathways in achieving a push to establish primary care services, provider enablement, and home health.

Investigators also report that the therapy could mimic the efficacy of olanzapine but cancelled out the medication-induced weight gain, improving symptoms and outcomes.

A P79S ORF2 variant demonstrates reduced RNA copy numbers released in the supernatant and impaired the production of infectious disease particles, investigators said.

Investigators report that while lateral flow tests do not detect the start of infectiousness well, they can identify individuals who will not infect others and can safely leave isolation.

Dundee Pharmacy’s compliance packaging encourages patients to stay adherent to their medications.

The regulatory submission includes data from the MOMENTUM phase 3 clinical trial that met all primary and key second efficacy end points.

University of Minnesota Medical School Analysis shows comparison with fluvoxamine and ivermectin in a double-blinded, placebo-controlled, randomized study.

The American Heart Association includes 6 conditions and indicates that men’s and women’s experiences may differ.

Investigators used the FDA-approved concussions test i-STAT TBI Plasma and the company’s core laboratory Architect instrument.

The treatment regimen is first in more than 20 years to significantly improve outcomes in individuals with the fast-growing cancer, according to the company.

Investigators find that establishing immunity in the mucosal areas establishes a frontline defense against these diseases.

Analysis is based on functional magnetic resonance imaging to provide insight into the effective connectivity.

The drug also meets the key secondary endpoint of improved overall survival for treatment for individuals with HER2 positive unresectable and/or metastatic breast cancer.

Study results show a compound annual growth rate of 5.2% from $392.4 billion in revenue in 2021.

Investigators from University of Texas Health Science Center at Houston analyze data from individuals aged 5 to 18 years enrolled in the Texas CARES survey.

The meta-analysis reviews 38 available studies on the effects of cognitive, physical, and social activities on brain function.

Analysis looks at those with arthritis, chronic pain, headaches, lower back pain, and neuropathic pain between 2012 and 2019.

Investigators aimed to determine how individuals with and without concomitant NSP differ in characteristics and in their perception of treatment responses to analgesics.

The company-sponsored phase 1/2 study evaluates a cryopreserved, readily available formulation for the treatment of follicular and diffuse large B cell lymphomas.

Health care providers’ recommendations will make a difference, results of a new poll from the University of Michigan show.

Topline results from the KarMMa-3 trial show that idecabtagene vicleucel significantly improves progression-free survival vs standard regimens.

Approximately 6000 participants aged 5 years and older at 50 sites in different countries are set to received 3 doses of VLA 15 µg or the saline placebo, followed by a booster.

The interim analysis of the TROPION-Lung02 trial demonstrate an overall response rate of 37% in individuals who were treated with datopotamab deruxtecan and pembrolizumab.

Analysis supports positive lifestyle habits, such as exercising and quitting smoking, investigators say.

Investigators from NYU’s Grossman School of Medicine sound alarm on treatment gap and suggest ways to remove barriers, as opioid overdoses soar to historic levels.

Study suggests that health care providers should discuss with patients whether they are using any integrative medicine strategies, which ones, and why.

The approval is based on results of the phase 3 study, ARASENS, that demonstrated a statistically significant increase in overall survival, the trial’s primary endpoint.

Preliminary data from the ongoing dose-escalation portion of the clinical trial, show dose-dependent anti-tumor activity when combined with standard-dose Libtayo.